-
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma's Investigational Antidepressant Targeting NET/DAT/GABAAR
SHANGHAI, Aug. 3, 2025 -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in China for its LY03021, which was filed through China's Class 1 pathway for innovative drugs. LY03021 is an inhibitor of the norepinephrine transporter (NET), the dopamine transporter (DAT), and a gamma-aminobutyric acid type A receptor-positive allosteric modulator (GABAAR PAM), intended for the treatment of Major Depressive Disorder (MDD). MDD has a high prevalence rate, a high disability rate, and a high recurrence rate. In China, the lifetime prevalence
- 김갑성 기자
- 2025-08-03 18:23
-
Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA
SHANGHAI, Aug. 1, 2025 -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance from China's National Medical Products Administration (NMPA) and an IND Acknowledgement Letter from the U.S. Food and Drug Administration (FDA). 7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell's proprietary IDDC™ platform. Its highly optimized structure integrates three key elements: Ma
- 김갑성 기자
- 2025-08-01 22:00
-
Everest Medicines Expands Strategic Investment in I-MAB
- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall response rate (ORR) of 83% in combination with immunotherapy in a Phase 1b trial of first line gastric cancers. - I-Mab's differentiated 4-1BB receptor targeting platform and bispecific antibody pipeline are highly complementary with the Company's existing mRNA cancer vaccines and in vivo CAR-
- 김갑성 기자
- 2025-08-01 21:02
-
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
SYDNEY, Aug. 1, 2025 -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional investors for a private placement of equity securities (PIPE). Pursuant to the securities purchase agreement, the Company agreed to offer and sell to an aggregate of approximately $2.0 million of ordinary shares and prefunded warrants. The securities being sold in the PIPE are priced at a 5% premium to the closing price of Kazia's ADSs on July 31, 2025. The PIPE is struc
- 김갑성 기자
- 2025-08-01 20:00
-
2025 알츠하이머 협회 국제 콘퍼런스(AAIC), 주요 연구 성과 발표
토론토, 2025년 8월1일 -- 알츠하이머 협회 국제 콘퍼런스® 2025(Alzheimer's Association International Conference®, AAIC®)에서 발표된 최신 연구 결과들이 알츠하이머병 및 기타 치매의 위험 요인, 진단, 치료에 대한 과학적 이해를 높였다. 주요 내용은 다음과 같다. 미국 POINTER 임상시험에서 인지 기능 저하 위험이 있는 노인에게 두 가지 생활 습관 개입이 인지 능력을 향상시켰다. 특히 체계적인 지원과 책임감을 강조한 개입은 자기 주도적 개입보다 더 큰 개선 효과를 보였으며, 최대 2년간 정상적인 노화 관련 인지 기능 저하를 예방하는 데 도움이 됐다. 알츠하이머 협회는 알츠하이머병 진단에 도움을 주기 위한 전문의의 혈액 바이오마커 검사 사용에 대한 첫 번째 임상진료지침(CPG)을 발표했다. 다섯 건의 연구 데이터에 따르면, 혈압, 콜레스테롤, 당뇨병 치료에 사용되는 일반적인 약물 조합이 인지 기능 저하를 늦출 수 있는 것으로 나타났다. 60만 명 이상을 대상으로 한 연구에서 대기 중 납과 환경에 존재하는 납이 50년 후의 기억력 문제와
- 김갑성 기자
- 2025-08-01 19:52
-
Atombeat and BioDuro Announce Strategic Partnership to Launch an AI-Powered Platform for Accelerated Peptide Drug Discovery
SAN DIEGO, Aug. 1, 2025 -- On July 30, 2025, Atombeat Inc., a leading force in AI for drug discovery, and BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO), announced a strategic collaboration to an AI powered platform for accelerated peptide drug discovery. This collaboration brings together Atombeat's in silico modeling expertise, AI-accelerated & data-driven design platform with BioDuro's expertise in discovery chemistry, biology and DMPK to accelerate the development of next-generation peptides. By enabling a seamless end
- 김갑성 기자
- 2025-08-01 18:08
-
Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson's Disease
[ 메디채널 김갑성 기자 ] The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational drug in 24 healthy subjects. The results confirmed the favorable safety and tolerability profile of ENERGI-F705PD and successfully validated its sustained-release oral formulation. Energenesis plans to advance ENERGI-F705PD into a Phase II trial. TAIPEI, Aug. 1, 2025 -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company focused on cellular e
- 김갑성 기자
- 2025-08-01 15:52
-
ASPIRE for Lung Cancer launches the APAC Lung Cancer Policy Consensus as a regional call to action for improved lung cancer care
SINGAPORE, Aug. 1, 2025 -- On 31st July 2025, a unified consensus document for improving lung cancer care in the Asia-Pacific (APAC) region was officially launched in Singapore, marking a pivotal moment in the regional fight against lung cancer. This represents the first comprehensive consensus for the region, an evidence-based agreement between stakeholders across the healthcare ecosystem that outlines shared priorities, strategies, and recommendations to elevate the standard of lung cancer care across diverse health systems. Held on the eve of World Lung Cancer Day, the initiative in
- 김갑성 기자
- 2025-08-01 15:02
-
Herbalgy Trophy Wraps Up with a Thrilling 1-0 Victory Tottenham for Over Arsenal
Football Fever Grips Hong Kong as nearly 50,000 Fans Pack Kai Tak Download high-resolution images: http://bit.ly/45dBPVk HONG KONG, Aug. 1, 2025 -- The Herbalgy Trophy: Arsenal vs Tottenham Hotspur, the flagship match of the Hong Kong Football Festival 2025, proudly presented by leading Hong Kong wellness brand Herbalgy, reached its spectacular finale on July 31 at the Main Stadium of Kai Tak Sports Park. In the first-ever North London Derby held outside the UK, English Premier League giants Arsenal and Tottenham Hotspur delivered a thrilling encounter. Wi
- 황정호 기자
- 2025-08-01 12:59
-
GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader
PISCATAWAY, N.J., Aug. 1, 2025 -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that its ESG rating has been upgraded to AA from A by MSCI in recognition of the company's excellence in the areas of product safety & quality and human capital development, as well as continuous improvement in environment and governance practices. MSCI, one of the world's largest index providers, evaluates global public and private companies on a scale from CCC (laggard) to AAA (leader), according to exposure to i
- 김갑성 기자
- 2025-08-01 10:02
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-08-31_SUN
2025-08-30_SAT
- Global Trade Review Announces GTR Asia 2025 in Singapore - the premier platform for the trade community in the Asia Pacific region - hits over 1,500 registration for September 2-3 23:39
- SENGKANG GENERAL HOSPITAL HOLDS MEN'S HEALTH FORUM TO CHAMPION PREVENTIVE CARE AND WELLBEING AMONG MEN IN SINGAPORE 21:33
- 成長への入り口：第8回CIIEにおけるイノベーションと機会 20:57
- 성장의 관문: 제8회 CIIE의 혁신과 기회 20:44
- 제이씨바이오•MGI 테크, 한국 내 멀티오믹스 혁신 촉진 위한 DCS 연구소 프로젝트 협력 발표 15:37
- Global Launch of AEROVENT ZERO: China-Developed Innovation Ushering Tech Textiles into a PFAS-Free Era 15:16
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 08월 31일 05시 20분